Table 1.23

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Both Sexes

All Races			White			Black		
	$Rate^b$	APC ^c		$Rate^{b}$	APC ^c		Rateb	APC ^c
	2013-2017	2008-2017		2013-2017	2008-2017		2013-2017	2008-2017
All Sites	442.4	-1.1*	All Sites	452.1	-1.1*	All Sites	440.4	-1.6*
Breast	68.9	0.0	Breast	69.5	-0.2	Prostate ^f	74.4	-4.2*
Lung and Bronchus	54.2	-2.2*	Lung and Bronchus	56.0	-2.2*	Breast	71.3	0.2
Prostate ^f	50.2	-4.3*	Prostate ^f	47.3	-4.8*	Lung and Bronchus	54.8	-2.7*
Colon and Rectum	38.2	-2.3*	Colon and Rectum	37.8	-2.2*	Colon and Rectum	43.6	-3.0*
Melanoma of the Skin	22.7	1.2*	Melanoma of the Skin	27.2	1.3*	Kidney and Renal Pelvis	17.5	0.1
Urinary Bladder	20.0	-1.4*	Urinary Bladder	22.0	-1.4*	Corpus and Uterus, NOS ^f	15.9	1.5*
Non-Hodgkin Lymphoma	19.6	-0.8*	Non-Hodgkin Lymphoma	20.6	-0.8*	Pancreas	15.3	0.1
Kidney and Renal Pelvis	16.3	0.4*	Kidney and Renal Pelvis		0.5*	Non-Hodgkin Lymphoma	14.7	-0.5*
Thyroid	15.7	1.0	Thyroid	16.4	0.7	Myeloma	13.8	0.3
Corpus and Uterus, ${ m NOS}^{ m f}$	14.8	0.9*	Leukemia	15.0	-0.4	Urinary Bladder	11.8	-0.8*
Leukemia	14.1	-0.3	Corpus and Uterus, NOS ^f	14.9	0.6*	Leukemia	10.8	0.3
Pancreas	13.1	0.5*	Pancreas	13.1	0.5*	Liver & IBD ^g	10.7	0.7
Oral Cavity and Pharynx	11.4	0.5*	Oral Cavity and Pharynx	12.0	0.6*	Stomach	10.1	-2.1*
Liver & IBD ^g	9.0	1.4*	Liver & IBD ^g	8.1	1.9*	Thyroid	9.5	1.3
Stomach	7.3	-0.8*	Brain and ONS ^g	7.1	-0.7*	Oral Cavity and Pharynx	8.5	-1.2*
Asian/Pacific	: Islander		American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rateb	APC ^c
	2013-2017	2008-2017		2013-2017	2008-2017		2013-2017	2008-2017
All Sites	302.1	-0.8*	All Sites	310.1	-1.0*	All Sites	348.4	-1.1*
Breast	56.3	1.2*	Breast	42.7	-0.5	Breast	53.2	0.4
Lung and Bronchus	36.2	-1.1*	Colon and Rectum	39.0	-1.1	Prostate ^f	40.7	-5.5*
Colon and Rectum	31.8	-2.5*	Lung and Bronchus	38.1	-1.8*	Colon and Rectum	33.7	-1.8*
Prostate ^f	25.1	-4.9*	Prostate ^f	24.3	-5.4*	Lung and Bronchus	29.0	-2.2*
Thyroid	15.8	1.2*	Kidney and Renal Pelvis	17.9	-0.3	Non-Hodgkin Lymphoma	18.1	-0.4*
Non-Hodgkin Lymphoma	13.5	-0.5	Liver & IBD ^g	14.9	1.2	Kidney and Renal Pelvis	16.1	1.0*
Liver & IBD ^g	12.9	-2.2*	Non-Hodgkin Lymphoma	10.9	-3.3*	Thyroid	14.2	2.3*
Corpus and Uterus, NOS ^f	11.8	1.9*	Corpus and Uterus, NOS ^f	10.6	-0.8	Liver & IBD ^g	13.7	0.6
Stomach	10.6	-2.6*	Pancreas	10.0	1.1	Corpus and Uterus, NOS ^f	13.1	2.1*
Pancreas	10.0	0.3	Urinary Bladder	9.6	1.6	Pancreas	11.6	0.1
Urinary Bladder	8.9	-0.9*	Thyroid	9.3	2.3*	Urinary Bladder	11.0	-1.5*
Kidney and Renal Pelvis	8.8	0.8	Stomach	8.4	-1.3	Leukemia	10.9	-0.6
Oral Cavity and Pharynx	8.5	0.4	Oral Cavity and Pharynx	8.1	-0.4	Stomach	10.5	-1.2*
Leukemia	8.0	-0.4	Leukemia	8.1	-0.8	Oral Cavity and Pharynx	6.8	-1.2*
Ovary ^{fh}	5.1	-1.0	Myeloma	5.7	2.9	Myeloma	6.8	0.2

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

- ^a Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.
- ^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- ^c The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- ^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
- e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
- Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- ^f The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
- ^g IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.24

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Males

All Races			White			Black		
	Rate ^b	APC ^c		Rate ^b	APC ^c		$Rate^{b}$	APC ^c
	2013-2017	2008-2017		2013-2017	2008-2017		2013-2017	2008-2017
All Sites	480.3	-1.9*	All Sites	485.5	-1.9*	All Sites	515.1	-2.7*
Prostate	109.8	-4.5*	Prostate	102.3	-5.0*	Prostate	175.2	-4.5*
Lung and Bronchus	61.7	-2.9*	Lung and Bronchus	62.2	-2.9*	Lung and Bronchus	71.2	-3.5*
Colon and Rectum	43.7	-2.4*	Colon and Rectum	43.0	-2.4*	Colon and Rectum	51.3	-3.0*
Urinary Bladder	34.9	-1.6*	Urinary Bladder	38.2	-1.6*	Kidney and Renal Pelvis	24.5	0.1
Melanoma of the Skin	29.3	1.1*	Melanoma of the Skin	34.6	1.2*	Urinary Bladder	19.7	-1.1*
Non-Hodgkin Lymphoma	23.8	-0.8*	Non-Hodgkin Lymphoma	25.0	-0.8*	Liver & IBD ^f	17.7	0.7
Kidney and Renal Pelvis	22.4	0.4	Kidney and Renal Pelvis	23.0	0.4	Non-Hodgkin Lymphoma	17.7	-1.0*
Leukemia	18.1	-0.4	Leukemia	19.2	-0.5	Pancreas	16.9	-0.1
Oral Cavity and Pharynx	17.2	0.6*	Oral Cavity and Pharynx	18.1	0.8*	Myeloma	16.5	0.2
Pancreas	14.9	0.5*	Pancreas	15.0	0.6*	Stomach	13.8	-2.3*
Liver & IBD ^f	13.8	1.1*	Liver & IBD ^f	12.4	1.5*	Leukemia	13.6	-0.1
Stomach	9.9	-1.3*	Stomach	8.9	-1.4*	Oral Cavity and Pharynx	13.3	-1.3*
Myeloma	8.8	0.6	Thyroid	8.6	1.4*	Larynx	7.3	-3.1*
Thyroid	8.1	1.5*	Brain and ONS ^f	8.3	-0.8*	Esophagus	6.1	-4.5*
Brain and ONS^{f}	7.5	-0.8*	Myeloma	8.2	0.5	Brain and ONS^{f}	4.5	-1.1
Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
Asian/Pacific	Islander		American Indian/A	Alaska Nati	ive ^d	Hispan	ice	
Asian/Pacific	Islander Rate ^b	APC ^c	American Indian/i		ive ^d APC ^c	Hispan	-	APC ^c
		APC ^c 2008-2017		Alaska Nati Rate ^b 2013-2017	APC ^c	Hispan	<u>ic^e</u> Rate ^b 2013-2017	APC ^c 2008-2017
	Rate ^b			Rate ^b	APC ^c	<u>Hispan</u>	Rate ^b	
	Rate ^b 2013-2017	2008-2017		Rate ^b 2013-2017	APC ^c 2008-2017		Rate ^b 2013-2017	2008-2017
All Sites	Rate ^b 2013-2017 304.4	2008-2017 -1.9*	All Sites	Rate ^b 2013-2017 321.0	APC ^c 2008-2017 -1.6*	All Sites	Rate ^b 2013-2017 370.4	2008-2017 -2.5*
All Sites Prostate	Rate ^b 2013-2017 304.4 56.7	<u>2008-2017</u> -1.9* -5.0*	All Sites Prostate	Rate ^b 2013-2017 321.0 54.6	APC ^c 2008-2017 -1.6* -5.4*	All Sites Prostate	Rate ^b 2013-2017 370.4 92.0	<u>2008-2017</u> -2.5* -5.8*
All Sites Prostate Lung and Bronchus	Rate ^b 2013-2017 304.4 56.7 46.2	<u>2008-2017</u> -1.9* -5.0* -1.9*	All Sites Prostate Lung and Bronchus	Rate ^b 2013-2017 321.0 54.6 43.5	APC ^c 2008-2017 -1.6* -5.4* -2.6*	All Sites Prostate Colon and Rectum	Rate ^b 2013-2017 370.4 92.0 39.6	<u>2008-2017</u> -2.5* -5.8* -2.5*
All Sites Prostate Lung and Bronchus Colon and Rectum	Rate ^b 2013-2017 304.4 56.7 46.2 37.9	2008-2017 -1.9* -5.0* -1.9* -2.2*	All Sites Prostate Lung and Bronchus Colon and Rectum	Rate ^b 2013-2017 321.0 54.6 43.5 40.4	APC ^c 2008-2017 -1.6* -5.4* -2.6* -2.4*	All Sites Prostate Colon and Rectum Lung and Bronchus	Rate ^b 2013-2017 370.4 92.0 39.6 35.1	2008-2017 -2.5* -5.8* -2.5* -3.2*
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1*	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9	APC ^c 2008-2017 -1.6* -5.4* -2.6* -2.4* -0.8	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4	2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5	<u>2008-2017</u> -1.9* -5.0* -1.9* -2.2* -2.1* -0.5	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6	APC ^c <u>2008-2017</u> -1.6* -5.4* -2.6* -2.4* -0.8 1.4	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9	<u>2008-2017</u> -2.5* -5.8* -2.5* -3.2* 0.8 -0.6
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1* -0.5 -0.9*	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3	APC ^c - <u>2008-2017</u> -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3	2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8 -0.6 0.1
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1 12.5	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1* -0.5 -0.9* -2.5*	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9	APC ^c - <u>2008-2017</u> -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3	2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8 -0.6 0.1 -1.6* -0.7
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1	$\begin{array}{r} 2008-2017 \\ -1.9^{*} \\ -5.0^{*} \\ -1.9^{*} \\ -2.2^{*} \\ -2.1^{*} \\ -0.5 \\ -0.9^{*} \\ -2.5^{*} \\ 0.6 \end{array}$	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas Oral Cavity and Pharynx Stomach	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9 11.7	APC ^c 2008-2017 -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8 -0.3 -1.8	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder Leukemia	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3 13.2	2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8 -0.6 0.1 -1.6*
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1 12.5 12.1	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1* -0.5 -0.9* -2.5* 0.6 0.1	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas Oral Cavity and Pharynx	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9 11.7 11.1	APC ^c <u>2008-2017</u> -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8 -0.3	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder Leukemia Stomach	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3 13.2 13.1 12.5	2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8 -0.6 0.1 -1.6* -0.7 -2.2*
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1 12.5 12.1 11.0	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1* -0.5 -0.9* -2.5* 0.6 0.1 0.3	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas Oral Cavity and Pharynx Stomach Non-Hodgkin Lymphoma	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9 11.7 11.1 10.8	APC ^c <u>2008-2017</u> -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8 -0.3 -1.8 -5.2*	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder Leukemia Stomach Pancreas	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3 13.2 13.1 12.5	- 2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8 -0.6 0.1 -1.6* -0.7 -2.2* 0.0
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia Thyroid	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1 12.5 12.1 11.0 9.9	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1* -0.5 -0.9* -2.5* 0.6 0.1 0.3 -0.3	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas Oral Cavity and Pharynx Stomach Non-Hodgkin Lymphoma Leukemia Myeloma	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9 11.7 11.1 10.8 10.7	APC ^c 2008-2017 -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8 -0.3 -1.8 -5.2* 1.2	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder Leukemia Stomach Pancreas Oral Cavity and Pharynx Myeloma	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3 13.2 13.2 13.1 12.5 10.0	- 2008-2017 -2.5* -5.8* -2.5* -3.2* 0.8 -0.6 0.1 -1.6* -0.7 -2.2* 0.0 -1.4
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia Thyroid Myeloma	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1 12.5 12.1 11.0 9.9 7.9	2008-2017 -1.9* -5.0* -1.9* -2.2* -2.1* -0.5 -0.9* -2.5* 0.6 0.1 0.3 -0.3 2.8*	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas Oral Cavity and Pharynx Stomach Non-Hodgkin Lymphoma Leukemia Myeloma Esophagus	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9 11.7 11.1 10.8 10.7 6.7 6.2	APC ^c 2008-2017 -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8 -0.3 -1.8 -5.2* 1.2	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder Leukemia Stomach Pancreas Oral Cavity and Pharynx	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3 13.2 13.1 12.5 10.0 8.2 5.9	$\begin{array}{r} 2008-2017\\ -2.5*\\ -5.8*\\ -2.5*\\ -3.2*\\ 0.8\\ -0.6\\ 0.1\\ -1.6*\\ -0.7\\ -2.2*\\ 0.0\\ -1.4\\ -0.1 \end{array}$
All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD ^f Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia Thyroid	Rate ^b 2013-2017 304.4 56.7 46.2 37.9 19.9 16.5 15.7 14.1 12.5 12.1 11.0 9.9 7.9 5.0	$\begin{array}{c} 2008-2017\\ -1.9^{*}\\ -5.0^{*}\\ -1.9^{*}\\ -2.2^{*}\\ -2.1^{*}\\ -0.5\\ -0.9^{*}\\ -2.5^{*}\\ 0.6\\ 0.1\\ 0.3\\ -0.3\\ 2.8^{*}\\ 0.1 \end{array}$	All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD ^f Urinary Bladder Pancreas Oral Cavity and Pharynx Stomach Non-Hodgkin Lymphoma Leukemia Myeloma	Rate ^b 2013-2017 321.0 54.6 43.5 40.4 22.9 21.6 16.3 12.9 11.7 11.1 10.8 10.7 6.7	APC ^c 2008-2017 -1.6* -5.4* -2.6* -2.4* -0.8 1.4 0.5 2.8 -0.3 -1.8 -5.2* 1.2	All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD ^f Urinary Bladder Leukemia Stomach Pancreas Oral Cavity and Pharynx Myeloma Thyroid	Rate ^b 2013-2017 370.4 92.0 39.6 35.1 21.4 20.9 20.3 19.3 13.2 13.1 12.5 10.0 8.2	$\begin{array}{c} 2008-2017\\ -2.5*\\ -5.8*\\ -2.5*\\ -3.2*\\ 0.8\\ -0.6\\ 0.1\\ -1.6*\\ -0.7\\ -2.2*\\ 0.0\\ -1.4\\ -0.1\\ 3.0* \end{array}$

- Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
- а Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.
- b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- С The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130). d
 - Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
- P Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. f
- IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.25

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Females


All Races			White			Black		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2013-2017	2008-2017		2013-2017	2008-2017		2013-2017	2008-2017
All Sites	418.3	-0.3*	All Sites	432.0	-0.4*	All Sites	390.7	-0.4*
Breast	128.5	0.2	Breast	131.3	0.0	Breast	124.8	0.3
Lung and Bronchus	48.6	-1.5*	Lung and Bronchus	51.5	-1.5*	Lung and Bronchus	43.8	-2.0*
Colon and Rectum	33.6	-2.2*	Colon and Rectum	33.3	-2.0*	Colon and Rectum	38.2	-3.0*
Corpus and Uterus, NOS	27.8	1.0*	Corpus and Uterus, NOS	28.3	0.7*	Corpus and Uterus, NOS	27.9	1.7*
Thyroid	23.1	0.8	Thyroid	24.3	0.6	Thyroid	14.3	1.5
Melanoma of the Skin	17.8	1.3*	Melanoma of the Skin	21.7	1.4*	Pancreas	14.1	0.3
Non-Hodgkin Lymphoma	16.2	-0.8*	Non-Hodgkin Lymphoma	17.0	-0.9*	Non-Hodgkin Lymphoma	12.5	0.0
Pancreas	11.6	0.4*	Ovary ^g	11.7	-2.4*	Kidney and Renal Pelvis	12.2	-0.2
Ovary ^g	11.2	-2.1*	Leukemia	11.6	-0.4	Myeloma	12.0	0.3
Kidney and Renal Pelvis	11.1	0.3	Pancreas	11.6	0.4	Ovary ^g	9.1	-1.4*
Leukemia	11.0	-0.3	Kidney and Renal Pelvis	11.4	0.4	Leukemia	8.9	0.7
Urinary Bladder	8.6	-1.5*	Urinary Bladder	9.4	-1.5*	Cervix Uteri	8.7	-2.4*
Cervix Uteri	7.4	-0.7	Cervix Uteri	7.2	-0.7	Stomach	7.6	-2.1*
Oral Cavity and Pharynx	6.4	0.1	Oral Cavity and Pharynx	6.6	0.2	Urinary Bladder	6.5	-0.4
Myeloma	5.7	0.6*	Brain and ONS ^f	6.0	-0.6	Liver $\stackrel{-}{\&}$ IBD ^f	5.4	0.8
Asian/Pacific	: Islander		American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2013-2017	2008-2017		2013-2017	2008-2017		2013-2017	2008-2017
All Sites	304.7	0.0	All Sites	305.9	-0.4	All Sites	339.5	0.2
Breast	102.9	1.2*	Breast	79.5	-0.5	Breast	99.1	0.6*
Lung and Bronchus	28.6	-0.2	Colon and Rectum	37.9	0.0	Colon and Rectum	29.2	-1.1*
Colon and Rectum	26.8	-3.0*	Lung and Bronchus	34.3	-1.0	Lung and Bronchus	24.8	-1.2*
Thyroid	22.7	0.8	Corpus and Uterus, NOS	19.9	-0.8	Corpus and Uterus, NOS	24.6	2.4*
Corpus and Uterus, NOS	21.7	1.9*	Thyroid	14.5	2.6*	Thyroid	22.3	2.3*
Non-Hodgkin Lymphoma	11.1	-0.6	Kidney and Renal Pelvis	13.7	-0.1	Non-Hodgkin Lymphoma	15.9	-0.2
Ovary ^g	9.5	-1.0	Non-Hodgkin Lymphoma	10.9	-1.2	Kidney and Renal Pelvis	11.7	1.1*
Pancreas	9.2	0.2	Liver & IBD ^f	9.0	0.7	Pancreas	10.8	0.2
Stomach	8.0	-2.9*	Ovary ^g	8.4	-3.2	Ovary ^g	10.4	-0.9*
Liver & IBD ^f	7.2	-2.5*	Cervix Uteri	7.9	0.4	Cervix Uteri	9.2	-1.9*
Leukemia	6.5	-0.8	Pancreas	7.8	-0.6	Leukemia	9.1	-0.6
Cervix Uteri	6.5	-0.5	Stomach	6.2	-1.1	Stomach	8.6	-0.2
Kidney and Renal Pelvis	5.8	1.0	Leukemia	6.0	-3.4	Liver & IBD ^f	8.1	1.6*
Oral Cavity and Pharynx	5.5	1.0	Myeloma	5.0	-0.2	Myeloma	5.7	0.3
Urinary Bladder	3.8	-1.6*	Melanoma of the Skin	5.0	-	Urinary Bladder	5.0	-1.9*

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

- Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.
- ^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- ^c The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- ^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
- e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
- Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- ^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Figure 1.13

SEER Incidence 2008-2017 Males by Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG), Idaho, New York and Massachusetts.


Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.8, April 2020, National Cancer Institute.

- ^a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.
- ^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Figure 1.14

SEER Incidence 2008-2017 Females by Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG), Idaho, New York and Massachusetts.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.8, April 2020, National Cancer Institute.

- ^a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.
- ^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.